Quale sarebbe il prezzo per Biocartis Group N.V. (BCART)

Il prezzo per Biocartis Group N.V. (BCART) è $0.343985

Qual è la capitalizzazione di mercato per Biocartis Group N.V. (BCART)

La capitalizzazione di mercato per Biocartis Group N.V. (BCART) è $32.31M

Biocartis Group N.V. (BCART) Prezzo e Capitalizzazione di Mercato

Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.

Il prezzo per BCART	Attivo B	Capitalizzazione del mercato a B	Risultati
$56,439.04 $32.31M	NVDA	$5.301T	+16,407,312.61%
$49,337.40 $32.31M	AAPL	$4.634T	+14,342,793.63%
$44,110.86 $32.31M	GOOG	$4.143T	+12,823,383.89%
$38,216.52 $32.31M	MSFT	$3.589T	+11,109,838.98%
$30,418.31 $32.31M	AMZN	$2.857T	+8,842,816.89%

Il prezzo per BCART

Attivo B

Capitalizzazione del mercato a B

Risultati

$56,439.04 $32.31M